1,228 reports of this reaction
4.3% of all CEFEPIME HYDROCHLORIDE reports
#2 most reported adverse reaction
ACUTE KIDNEY INJURY is the #2 most commonly reported adverse reaction for CEFEPIME HYDROCHLORIDE, manufactured by Sagent Pharmaceuticals. There are 1,228 FDA adverse event reports linking CEFEPIME HYDROCHLORIDE to ACUTE KIDNEY INJURY. This represents approximately 4.3% of all 28,358 adverse event reports for this drug.
Patients taking CEFEPIME HYDROCHLORIDE who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is moderately reported among CEFEPIME HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to acute kidney injury, the following adverse reactions have been reported for CEFEPIME HYDROCHLORIDE:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 1,228 FDA reports for CEFEPIME HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 4.3% of all adverse event reports for CEFEPIME HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience acute kidney injury while taking CEFEPIME HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.